富马酸福莫特罗治疗哮喘疗效观察

Efficacy of Formoterol in asthmatic patients

目的 临床观察富马酸福莫特罗（ 安通克） 片剂治疗轻、中度支气管哮喘急性发作的临床疗效和不良反应。方法 支气管哮喘患者９０ 例，随机分成Ａ、Ｂ两组，Ａ 组６０ 例接受安通克片剂２片／ 次（４０μｇ／ 片） ，２ 次／ 天，口服治疗。Ｂ 组３０ 例接受安通克片剂１ 片／ 次，２ 次／ 天，口服治疗。两组治疗均为７ 天，对所有患者治疗前后的临床症状、肺功能及不良反应进行了随访观察和测定。结果 肺功能ＦＥＶ１ 改善Ａ 组好转率为８１ ．６７％ ，Ｂ组为８０ ．００ ％ 。治疗期间ＰＥＦ值早、晚测定均有不同程度的增加，且早、晚ＰＥＦ变异率趋向缩小，提示哮喘症状呈逐步稳定状态。Ａ、Ｂ两组咳嗽有效率分别为７６ ．６７％ 和７３．３３ ％ ；痰量减少症状改善有效率分别为７１．６７ ％ 和６３．３３ ％ ；喘息症状的改善有效率分别为８５ ％ 和７６．６７ ％ 。治疗期间Ａ 组出现心悸５ 例（８ ．３ ％ ） ，手抖３ 例（５ ．０ ％ ） ，头痛１ 例（１ ．６７ ％ ） 。Ｂ 组出现不良反应３ 例（１０ ％ ） ，均为心悸，症状较轻微，能继续接受治疗。结论 安通克片４０ ～８０μｇ／ 次，２ 次／ 天，口服对哮喘治疗效果明显；不良反应较少，且轻微，可供临床广泛使用。

Objective To study the clinical efficacy and adverse effects of Formoterol in patients with mild and moderate asthmatic episodic attack. Methods Ninety asthmatics were randomly allocated into two comparable groups, A and B, treated orally with Formoterol 80μg Bid or 40ug Bid, respectively for 7 days. Group A included sixty patients (male 33, female 27, mean age 38.25 years) and group B thirty patients (male 12, female 18, mean age 39.14 years). We observed the clinical symptoms, adverse effects and lung function of all patients before and after treatment. Results In Group A and B, after treatment, the rate of improvement were 81.67% and 80.00%, respectively. In both groups during treat ment, PEF all increased in the morning and evening and the rate of variation of PEF decreased, which showing tendenty toward stabilized state. In group A and B, the improvement in cough were 76.67% and 73.33%, respectively; dacreased expectoration in 71.67% and 63.33%, respectively; decrease of wheezing 85% and 76.67% respectively. Adverse effects: in group A, five patients had palptitation; three had tremor (5.0%) and one had headache (1.67%). In group B, three had palpitation (10%), without need to discontinue the treatrment. Conclusion In asthma patients, oral Formoterol 40～80μg Bid. is effective and with only mild side effects. Hence, 40～80μg Bid. can be adopted for wider use. (Shanghai Med J, 1999,22∶669 672)